The European Medicines Agency (EMA) said Thursday that most cases of the omicron variant of the coronavirus in the European Union appeared to be “mild.”
SIGHT: China approves emergency use of two COVID-19 drugs
“The cases appear to be mostly mild, but we need to gather more evidence to determine if the spectrum of severity of the disease caused by omicron is different from all the variants that have circulated so far”said Marco Cavaleri, head of vaccine strategy at the Amsterdam-based EMA.
The World Health Organization (WHO) said Wednesday that omicron appears to cause a higher rate of reinfection, but causes less severe symptoms.
Pfizer and BioNTech, meanwhile, insisted on the efficacy of their current vaccine against the variant.
“At this time, we do not have sufficient data on the impact of this variant on the efficacy of approved vaccines, but we are continually scanning the horizon for results in this regard”, Cavaleri added.
The EMA has so far approved four vaccines, two antibody treatments and has given the green light to the emergency use of the pill developed by Merck.
- Pfizer vaccine is effective against omicron variant after “three doses”
- COVID-19 | Are three doses of the Pfizer vaccine enough against Omicron?
- WHO advises against treating COVID-19 patients with convalescent plasma
- Ómicron: what is epistasis and why is it the key to understanding how dangerous the new variant of the coronavirus is
- Omicron: 5 Most Googled Questions About Variation (& Expert Answers)
- Omicron | Does the new variant cause a more serious disease?
- What does the Minsa vaccination card app have and what is missing?